ATE394377T1 - Quinolinon- und benzoxazinon-derivate und ihren anwendungen - Google Patents

Quinolinon- und benzoxazinon-derivate und ihren anwendungen

Info

Publication number
ATE394377T1
ATE394377T1 AT04718298T AT04718298T ATE394377T1 AT E394377 T1 ATE394377 T1 AT E394377T1 AT 04718298 T AT04718298 T AT 04718298T AT 04718298 T AT04718298 T AT 04718298T AT E394377 T1 ATE394377 T1 AT E394377T1
Authority
AT
Austria
Prior art keywords
quinolinone
applications
benzoxazinone derivatives
benzoxazinone
derivatives
Prior art date
Application number
AT04718298T
Other languages
English (en)
Inventor
Ralph Harris
David Repke
Russell Stabler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE394377T1 publication Critical patent/ATE394377T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
AT04718298T 2003-03-11 2004-03-08 Quinolinon- und benzoxazinon-derivate und ihren anwendungen ATE394377T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45357403P 2003-03-11 2003-03-11

Publications (1)

Publication Number Publication Date
ATE394377T1 true ATE394377T1 (de) 2008-05-15

Family

ID=32990787

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04718298T ATE394377T1 (de) 2003-03-11 2004-03-08 Quinolinon- und benzoxazinon-derivate und ihren anwendungen

Country Status (23)

Country Link
US (2) US6943169B2 (de)
EP (1) EP1603880B1 (de)
JP (1) JP4404893B2 (de)
KR (1) KR100691090B1 (de)
CN (1) CN100455570C (de)
AR (1) AR043510A1 (de)
AT (1) ATE394377T1 (de)
AU (1) AU2004220388B9 (de)
BR (1) BRPI0408204A (de)
CA (1) CA2518403A1 (de)
CL (1) CL2004000450A1 (de)
CO (1) CO5601030A2 (de)
DE (1) DE602004013560D1 (de)
ES (1) ES2305742T3 (de)
HR (1) HRP20050775A2 (de)
MX (1) MXPA05009523A (de)
MY (1) MY135470A (de)
NO (1) NO20054135L (de)
NZ (1) NZ541642A (de)
RU (1) RU2333204C2 (de)
TW (1) TWI289141B (de)
WO (1) WO2004080969A1 (de)
ZA (1) ZA200506831B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0308696B8 (pt) 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
US7592457B2 (en) * 2004-10-20 2009-09-22 Korea Research Institute Of Chemical Technology 3-aryl-3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same
EP2162135A4 (de) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc Zusammensetzungen, synthese und verfahren zur anwendung von atypischen antipsychotika auf chinolinon-basis
WO2009009134A1 (en) * 2007-07-11 2009-01-15 Dow Corning Corporation Compositions for delivering a drug
EP2508177A1 (de) 2007-12-12 2012-10-10 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2163541A1 (de) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazin-Derivate zur Bindung und Abbildung von Amyloidplaques und deren Verwendung
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
AU2012324015A1 (en) 2011-12-01 2013-06-20 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN114085179B (zh) * 2021-11-29 2024-05-03 福建科宏生物工程股份有限公司 一种n-乙酰基-5-甲氧基色胺的制备方法
EP4499067A4 (de) * 2022-03-30 2026-03-04 Univ Florida Verbindungen zur behandlung von psychostimulierendem missbrauch
WO2024163956A2 (en) * 2023-02-03 2024-08-08 University Of Florida Research Foundation, Incorporated Sigma receptor ligand compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3733321A (en) 1971-07-06 1973-05-15 Squibb & Sons Inc 1,4-benzothiazin-3-ones
US4078062A (en) 1976-10-28 1978-03-07 E. R. Squibb & Sons, Inc. Substituted 2H-1,4-benzothiazin-3(4H)-ones
AU594983B2 (en) * 1985-10-29 1990-03-22 Dainippon Pharmaceutical Co. Ltd. Novel quinoline derivatives and processes for preparation thereof
US4902684A (en) * 1988-06-20 1990-02-20 E. R. Squibb & Sons, Inc. Benzazepine and benzothiazepine derivatives
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
AU736256B2 (en) * 1997-07-11 2001-07-26 Smithkline Beecham Plc Novel compounds
CA2319554C (en) 1998-03-31 2005-06-28 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
CA2312953A1 (en) 1998-03-31 1999-10-07 Warner-Lambert Company Quinolones as serine protease inhibitors
PL343317A1 (en) 1998-03-31 2001-08-13 Warner Lambert Co Benzoxazinones/benzothiazinones as serine protease inhibitors
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US20020019395A1 (en) 2000-02-01 2002-02-14 Bing-Yan Zhu Indalone and benzimidazolone inhibitors of factor Xa
WO2001057003A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
AU2002220715A1 (en) * 2000-11-24 2002-06-03 Smithkline Beecham Plc Indolsulfonyl compounds useful in the treatment of cns disorders
HRP20040090A2 (en) * 2001-08-10 2004-12-31 Hoffmann La Roche Arylsulfonyl derivatives with 5-ht<sub>6</sub> receptor affinity
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物

Also Published As

Publication number Publication date
DE602004013560D1 (de) 2008-06-19
WO2004080969A1 (en) 2004-09-23
NZ541642A (en) 2008-03-28
US20040186092A1 (en) 2004-09-23
US7476675B2 (en) 2009-01-13
CN1759101A (zh) 2006-04-12
RU2333204C2 (ru) 2008-09-10
EP1603880A1 (de) 2005-12-14
TWI289141B (en) 2007-11-01
NO20054135D0 (no) 2005-09-06
CN100455570C (zh) 2009-01-28
AU2004220388B9 (en) 2010-01-07
AU2004220388B2 (en) 2009-12-10
KR100691090B1 (ko) 2007-03-12
JP4404893B2 (ja) 2010-01-27
CA2518403A1 (en) 2004-09-23
CO5601030A2 (es) 2006-01-31
MY135470A (en) 2008-04-30
JP2006515344A (ja) 2006-05-25
US20050261308A1 (en) 2005-11-24
AR043510A1 (es) 2005-08-03
CL2004000450A1 (es) 2005-01-07
HRP20050775A2 (en) 2006-10-31
ZA200506831B (en) 2006-06-28
ES2305742T3 (es) 2008-11-01
TW200424189A (en) 2004-11-16
AU2004220388A1 (en) 2004-09-23
RU2005131172A (ru) 2006-05-10
BRPI0408204A (pt) 2006-02-14
US6943169B2 (en) 2005-09-13
NO20054135L (no) 2005-09-23
MXPA05009523A (es) 2005-10-18
KR20050109078A (ko) 2005-11-17
EP1603880B1 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
ATE394377T1 (de) Quinolinon- und benzoxazinon-derivate und ihren anwendungen
DE602004020474D1 (de) Vegf-traps und deren therapeutische anwendungen
ATE521638T1 (de) Gegen angiopoietin-2 gerichtete antikörper und anwendungen davon
EP1781098A4 (de) Antimikrobielle geräte und zusammensetzungen
ATE472534T1 (de) Benzimidazolderivate: herstellung und pharmazeutische anwendungen
DE602004030308D1 (de) HF-Messer und Endoskopiegerät
EP1676215A4 (de) Dienst-discovery und publikation
ATE422495T1 (de) Antibakterielle naphthydrin- und quinolinderivate
DE502004009028D1 (de) Scheinwerfer und Scheinwerferelement
EP1891597A4 (de) Vereinigte verwaltung von abgabe, verabreichung und abbildung von radiopharmazeutika
DE602006007831D1 (de) N-alkylcarbonylaminosäureester und n-alkylcarbonylaminosäurelaktonverbindungen und anwendung davon
ATE471937T1 (de) Cyclopropylgruppensubstituierte oxazolidinonantibiotika und derivate davon
DE602008003575D1 (de) Piperidinverbindungen und anwendungen davon
EP1847541A4 (de) Kondensiertes pyrimidinderivat und anwendungen davon
DE602005003077D1 (de) Befestigung und Knopf
ATE455755T1 (de) Tetralin- und indanderivate und deren anwendungen
ATE371653T1 (de) Benzoxazinderivate und deren verwendungen
DE10338270B4 (de) Variator und Variatoranordnung
ATE442368T1 (de) 3-amino-2-arylpropylazaindole und anwendungen davon
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
DE602005025107D1 (de) Arylamin-zusammensetzung und organische elektrolumineszenzeinrichtung
DE602006017183D1 (de) Benzimidazolderivat und anwendung davon
DE602005026765D1 (de) Polygonspiegel und polygonspiegeleinrichtung
DE602004029488D1 (de) Leuchtstoffschirm und abbildungsbaugruppe
DE502004000216D1 (de) Doppelkupplungseinrichtung und Radiallagerungskonzept hierfür

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1603880

Country of ref document: EP

REN Ceased due to non-payment of the annual fee